The widespread adoption of inhibitors of cyclin dependent kinases 4 and 6 (CDK4/6i) for the treatment of advanced and metastatic estrogen receptor positive (ER+) breast cancer will fundamentally change the biology and natural history of a disease that effects a significant proportion of the population. This evidence concerns the gene ESR1 and breast carcinoma.